STAT+: AACR In 30 Seconds Highlights Revolution Medicines And RAS Inhibitors

22 Apr 20264 min read0 viewsVerified Feed

GIST

You’re reading the web version of STAT’s popup newsletter, AACR in 30 seconds, your guide to what’s happening at the American Association of Cancer Researchers’ annual meeting. This is the last edition of our pop-up newsletter.

We hope you’ve learned as much as we have. If you’re not already a STAT+ subscriber, consider it!

There’s currently a  60% off promotion  on annual subscriptions. In the meantime, thanks for joining us.

Overcoming resistance and RevMed’s next drug? In case you missed it, Revolution Medicines’ sessions yesterday were jam-packed with conference attendees.

While most of the media coverage focused on the daraxonrasib in frontline pancreatic cancer data, the company also revealed some activity in a new compound, RM-055. CEO Mark Goldsmith described it as being part of a new class of “catalytic inhibitors,” since it can slice off a phosphate from GTP-RAS, or the “on” form of RAS, and turn the protein off.

Clinical Editorial

Context and purpose

This brief summarizes a STAT News popup newsletter update from the AACR annual meeting, highlighting items that drew attention at Revolution Medicines’ sessions.

The source is a short conference report; broader details and full coverage were referenced as available on STAT+ but are not included in the excerpt.

Study/meeting focus and setting

The content derives from presentations at the American Association for Cancer Research annual meeting.
Revolution Medicines held multiple sessions that attracted substantial attendee interest.

Key signal reported about a new compound

Revolution Medicines described a novel agent, RM-055, characterized by the company’s CEO as a “catalytic inhibitor.”
The proposed mechanism is enzymatic removal of a phosphate from GTP-bound RAS (the active RAS form), thereby converting the protein to an inactive state.

Rationale and mechanistic context

The company framed RM-055’s potential in the context of resistance mechanisms to RAS-targeted therapies.
One documented resistance route noted in the report is amplification of mutant RAS alleles, which can increase cellular levels of the active oncoprotein and reduce inhibitor effectiveness.
RM-055’s catalytic capacity was presented as theoretically able to inactivate multiple mutant RAS proteins, potentially addressing resistance driven by protein overabundance.

Evidence and limitations in the source

The excerpt reports descriptions and claims made by company leadership at the meeting; primary data, trial design, safety, or quantitative results are not provided in the source material.
No independent corroboration, preclinical or clinical datasets, or detailed methods were included in the provided text.